To amend title XIX of the Social Security Act to remove direct sales of drugs near expiration during the COVID-19 emergency from the calculation of certain pricing metrics under the Medicaid program.
About This Bill
Committee
Latest Action · September 1, 2020
Referred to the House Committee on Energy and Commerce.
Surplus Utilization of Pharmaceutical Products Leveraged In Emergency Scenarios Act of 2020 or the SUPPLIES Act of 2020
This bill excludes certain short-dated drugs from rebate calculations under the Medicaid Drug Rebate Program during the public health emergency relating to COVID-19 (i.e., coronavirus disease 2019). Specifically, the bill excludes from such calculations direct sales of drugs that (1) have a shelf life of one year or more and expire one year after the date of sale, or (2) have a shelf life of less than one year and expire after the same number of days as the shelf life following the date of sale.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.